Cambridge Healthtech Training Seminars offer real-life case studies, problems encountered and solutions applied, and extensive coverage of the basic science underlying each topic. Experienced Training Seminar instructors offer a mix of formal lectures,
interactive discussions and activities to help attendees maximize their learning experiences. These immersive trainings will be of value to scientists from industry and academic research groups who are entering new fields – and to those working
in supporting roles that will benefit from an in-depth briefing on a specific aspect of the industry.
Monday, Tuesday August 5-6, 2019
Introduction to Cancer Immunotherapy Discovery and Development
Instructor: Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, a Miltenyi Biotec Company
This course will cover the recent advances in cancer immunotherapy discovery and development. Immune checkpoint inhibitors and CAR T therapies have recently gained regulatory approval in the US and the EU. TILs- and TCR -based therapies, as well
as cancer vaccines are areas of great promise. Combination therapies are contributing to the clinical progress where single therapies fail. Advances in high throughput sequencing and immunogenomics aid in identifying novel tumor antigens, improving
effector molecules and vaccines, and predicting clinical outcomes.
- History of Immunotherapy
- Monoclonal Antibodies
- Checkpoint Blockade Inhibitors
- Cancer Vaccines
- Combination Therapies
- HTS and Immunogenomics
- Clinical Progress to Date and Future Directions
Dina Schneider, PhD, Associate Director, Translational Research, Lentigen Technology, a Miltenyi Biotec Company
Dina Schneider, BSPharm, PhD, is a scientist and inventor with over 15 years of experience in academia and industry. Dr. Schneider earned her PhD from Michigan State University and did her postdoctoral training at the University of Michigan. Her academic
career spanned diverse areas of interest, including cellular and molecular immunology, immunotoxicology, inflammation, and molecular biology. In 2011, Dr. Schneider transitioned to industry, where she contributed to numerous projects in synthetic
immunology, immunotherapy, and chimeric antigen receptor (CAR) T cell-based therapy. Dr. Schneider leads the Translational Research group at Lentigen Technology, Inc., a Miltenyi Biotec Company, in Gaithersburg, MD. Her group is focused on pre-clinical
development of novel CAR-based therapies targeting hematologic malignancies as well as solid tumors, and on the implementation of CliniMACS Prodigy® clinical platform for preparation of cell-based therapeutics. Her recent work includes the development
of novel CAR therapies, three of which are now in the clinic.